PharmaShots | Incisive News in 3 Shots

Subscribe Now

Classical Hodgkin Lymphoma

$Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma$

Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma

January 19, 2021

$Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Relapsed or Refractory Classical Hodgkin Lymphoma$

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Relapsed or Refractory Classical Hodgkin Lymphoma

October 16, 2020

BeiGene's Tislelizumab Receives NMPA's Approval for the Treatment of 2L Classical Hodgkin's Lymphoma (cHL)

BeiGene's Tislelizumab Receives NMPA's Approval for the Treatment of 2L Classical Hodgkin's Lymphoma (cHL)

December 31, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us